Rob Friederichs, PhD
Expert in Experimental Design, Model Development & Preclinical Program Coordination
Rob Friederichs, PhD
Expert in Experimental Design, Model Development & Preclinical Program Coordination
Professional Summary
Dr. Rob Friederichs is a versatile preclinical strategist with 15 years of industry experience guiding cardiovascular and structural-heart devices from concept to first-in-human use. Recognized for transforming complex technical questions into clear, hypothesis-driven study plans, Rob designs robust programs, defines meaningful endpoints, and assembles the right experts from our network—allowing small-to-mid-size biotech teams to advance rapidly and confidently through every stage of product development.
At Endpoint Preclinical, Rob serves as an Advanced Study Coordinator—partnering with clients to fast-track their preclinical programs. He collaborates closely with sponsors to plan studies, select models, establish endpoints, and integrate the necessary expertise from his colleagues across the Endpoint network to maximize impact and efficiency.
Core Competencies
- Program Coordination & Study Planning: Leads end-to-end study design: model selection, endpoint definition, timeline alignment, and cross-functional team orchestration.
- Model Development & Optimization: Pioneered CT-planned interventional procedures, perfused cadaveric vascular models, and ex vivo flow systems to address boundary-condition and failure-mode questions.
- Multimodal Data Analysis & Interpretation: Quantifies device and vessel deformation, pressure-flow relationships, and biomarker shifts using CT, TEE, IVUS, OCT, and fluoroscopy.
- Regulatory Strategy & Reporting: Crafts GLP-compliant protocols, defends boundary conditions and safety data to global regulators, and delivers concise, decision-ready reports.
- Risk Assessment & Product Development: Applies proactive experimentation and 3Rs principles to de-risk designs while accelerating verification and validation milestones.
Personal Philosophy
Rob’s commitment to scientific integrity is deeply personal: his wife’s life was saved by an innovative medical device. That experience anchors every project he undertakes, reminding him that rigorous preclinical work ultimately touches patients and families. He believes that clear problem definition, thoughtful upfront planning, and agile collaboration are essential to delivering safe, effective therapies quickly.